US Edition
Published • loading... • Updated
Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat
Summary by tickerreport.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat
Precigen (NASDAQ:PGEN) executives used a fireside chat hosted by H.C. Wainwright to outline the company’s transition into a commercial-stage organization following the FDA approval of Papzimeos, the first immunotherapy approved for adults with recurrent respiratory papillomatosis (RRP). The discussion, led by Swayampakula Ramakanth, managing director and senior equity analyst at H.C. Wainwright, featured President and […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
